BD Oncomark™ CD103/CD22/CD20 - SFDA Registration ME0000002814SFDAA00252
Access comprehensive regulatory information for BD Oncomark™ CD103/CD22/CD20 in the Saudi Arabia medical device market through Pure Global AI's free database. This General IVD(Others) device is registered with Saudi Arabia SFDA under registration number ME0000002814SFDAA00252 and manufactured by Becton, Dickinson and Company, BD Biosciences.
This page provides complete registration details including product category (Chemicals), manufacturer information, model details, and regulatory compliance data from the official Saudi Arabia SFDA medical device database. Pure Global AI offers free access to Saudi Arabia's complete medical device registry, helping global MedTech companies navigate SFDA regulations efficiently.
Anti CD103/CD22/CD20 for flow cytometer
BD Oncomark™ CD103 FITC/CD22 PE/ CD20 PerCP-Cy™5.5* is intended for in vitro flow cytometric immunophenotyping of normal and abnormal subsets of B lymphocytes. The reagents detect expression of the CD103, CD22, and CD20 antigens. These antigens are highly expressed in the abnormal cells of hairy-cell leukemia. A subset of normal B cells expressing CD103 has been identified in peripheral blood.1 CD103/CD22/CD20 assays are used in the diagnosis of hematologic disorders.
[]